Silas Inman

Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at


Pamrevlumab May Address Unmet Need for Locally Advanced Pancreatic Cancer

February 17th 2021

February 17, 2021 – Pamrevlumab, a first-in-class inhibitor of connective tissue growth factor activity, is being evaluated in combination with gemcitabine and nab-paclitaxel (Abraxane) in a phase 3 trial for patients with unresectable locally advanced pancreatic cancer, a population in need of new options.

Gottlieb Addresses Coronavirus, Innovation in Keynote Address

March 8th 2020

The novel coronavirus spreading across the world represents a distinct challenge for all physicians, especially oncologists who commonly treat patients who have compromised immune systems.

Gene Profiling Essential Tool for Treatment Tailoring

March 7th 2020

Gene profiling assays can accurately and reproducibly assist decision making for patients with hormone receptor-positive breast cancer, with the ultimate goal of improving outcomes or avoiding toxicity.

Updated bb21217 Data Continue to Impress in Multiple Myeloma

December 11th 2019

The CAR T cell therapy bb21217 demonstrated high very good partial response or better rates in patients with heavily pretreated relapsed/refractory multiple myeloma.

Navitoclax Overcomes Ruxolitinib Resistance for Myelofibrosis

December 10th 2019

Navitoclax plus ruxolitinib (Jakafi) showed clinically meaningful spleen responses and improvements in symptoms for patients with primary or secondary myelofibrosis, following the development of resistance to frontline ruxolitinib.

Maintenance CC-486 Improves Survival for Older Patients With AML

December 10th 2019

Maintenance treatment with CC-486, an oral formulation of azacitidine, extended median overall survival by 9.9 months compared with placebo for older patients with acute myeloid leukemia in first remission.

KTE-X19 Shows High CR Rates for MCL, FDA Submission Planned

December 10th 2019

Treatment with the anti-CD19 CAR T-cell therapy KTE-X19 elicited a complete remission rate of 67% and an objective response rate of 93% for patients with relapsed/refractory mantle cell lymphoma.

CPI-0610 Shows Strong Efficacy Signals for Advanced Myelofibrosis

December 10th 2019

CPI-0610 showed promising spleen volume responses and a meaningful reduction in total symptom score as monotherapy and in combination with ruxolitinib (Jakafi) for patients with refractory or intolerant advanced myelofibrosis.

Zanubrutinib Effective in CLL/SLL, Regardless of Del(17p) Status

December 9th 2019

The BTK inhibitor zanubrutinib continues to demonstrate high overall response rates for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, regardless of the presence of high-risk cytogenetics.

LOXO-305 Is Highly Effective in Heavily Pretreated B-cell Malignancies

December 9th 2019

More than half of patients with heavily pretreated B-cell malignancies responded to the noncovalent BTK inhibitor LOXO-305, including those with resistance or intolerance to other BTK inhibitors or BCL2 inhibitors.

Novel Triplet Shows Early Promise for Pretreated CLL

December 8th 2019

The triplet of umbralisib, ublituximab, and venetoclax induced a complete remission rate of 44% as a treatment for patients with relapsed/refractory chronic lymphocytic leukemia.

Axi-Cel Elicits 47% 3-Year OS Rate in B-Cell Lymphoma

December 8th 2019

The CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.

Anti-BCMA, CD3 Agent CC-93269 Shows Promise for Heavily Pretreated Myeloma

December 7th 2019

CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma.

Fate Touts Novel Off-the-Shelf Cell Therapy

December 7th 2019

An investigational new drug application for the therapy, which is labeled FT596, was approved in September 2019 and human trials are scheduled to begin in the first quarter of 2020.

Adjuvant Immunotherapy Combinations on Horizon for Melanoma

November 8th 2019

Quickly following on the approval of single agents, adjuvant immunotherapy combinations are quickly progressing through development, with promising signs of clinical activity seen in phase II studies, according to a presentation by Jeffrey S. Weber, MD, PhD, at the 37th Annual CFS®.

Novel Combinations Could Improve Cure Rates for Adult ALL

November 7th 2019

Novel combinations of biologic therapies, third-generation TKIs, and chemotherapy could lead to significantly higher cure rates for adult patients with acute lymphoblastic leukemia, with a number of early stage studies already showing promising results, according to Hagop M. Kantarjian, MD, at the 37th Annual CFS®.

Ripretinib Shows Dramatic PFS Improvement for Heavily Pretreated GIST

October 4th 2019

Treatment with the novel KIT and PDGFRA inhibitor ripretinib reduced the risk of progression or death by 85% compared with placebo for heavily pretreated patients with advanced gastrointestinal stromal tumors, according to findings from the phase III INVICTUS trial presented at the ESMO Congress 2019.

ClarIDHy Ivosidenib Data Practice-Changing for Advanced Cholangiocarcinoma

September 30th 2019

Treatment with ivosidenib reduced the risk of progression or death by 63% compared with placebo for pretreated patients with IDH1-mutant advanced cholangiocarcinoma.

Olaparib Doubles rPFS in Heavily Pretreated HRR+ mCRPC

September 30th 2019

Olaparib improved radiographic progression-free survival compared with physician's choice of abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene alterations.

Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected

September 29th 2019

The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates for patients with RET-mutant medullary thyroid cancer and in those with other RET fusion-positive thyroid cancer.